Press Releases

Date Title and Summary View
Toggle Summary Zosano Pharma Presents Migraine-ACT Scores for Qtrypta™ at the American Headache Society (AHS) Annual Scientific Meeting
Migraine Assessment of Current Therapy (or Migraine-ACT) Scores Highlight the Effectiveness of Qtrypta in Treating Migraines FREMONT, Calif. , July 15, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the presentation of
View HTML
Toggle Summary Zosano Pharma Announces Keynote Speech at the Pharmaceutics & Advanced Drug Delivery Systems Conference
FREMONT, Calif. , July 03, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that Hayley Lewis , senior vice president of operations at Zosano Pharma , will be presenting a keynote speech entitled, “A Novel Intracutaneous
View HTML
Toggle Summary Zosano Pharma Announces Upcoming Presentation at American Headache Society Annual Meeting
FREMONT, Calif. , July 01, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that a poster and e-poster describing Migraine-ACT scores, or measures of patient satisfaction with the management of their migraines, following
View HTML
Toggle Summary Zosano Pharma Completes Site Qualification Batches at Contract Manufacturing Organization as it Prepares for NDA Submission of Qtrypta™
Technical Transfer of manufacturing process to CMO signals commencement of commercial readiness activities NDA planned for Q4 2019 FREMONT, Calif. , June 18, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has
View HTML
Toggle Summary Zosano Pharma Reports First Quarter 2019 Financial Results
Multiple catalysts, including Qtrypta TM NDA submission, anticipated in 2019 Company bolstered balance sheet to advance proprietary programs and expand applicability of ADAM microneedle technology Conference call scheduled for 1:30 pm PT today FREMONT, Calif.
View HTML
Toggle Summary Zosano Announces Full Exercise of Underwriter’s Option to Purchase Additional Shares
FREMONT, Calif. , May 09, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has issued and sold an additional 750,000 shares of common stock, pursuant to the exercise in full of the underwriter’s option to purchase
View HTML
Toggle Summary Zosano Pharma to Host Conference Call on First Quarter 2019 Financial Results and Provide Operational Update
FREMONT, Calif. , May 08, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and webcast on Tuesday, May 14, 2019 at 4:30 p.m. ET to discuss results for the first quarter of 2019 and
View HTML
Toggle Summary Zosano Announces the Publication of an Analysis of Acute Treatments for Migraine in Headache: The Journal of Head and Face Pain
FREMONT, Calif. , April 16, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced the peer-reviewed publication of a review and analysis of recently-completed trials using newly FDA -recommended
View HTML
Toggle Summary Zosano Announces Pricing of Public Offering of Common Stock
FREMONT, Calif. , April 09, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of its common stock for gross proceeds of $17.5 million , before deducting underwriting discounts
View HTML
Toggle Summary Zosano Pharma Announces Proposed Public Offering of Common Stock
FREMONT, Calif. , April 08, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares to be sold in the offering will be offered
View HTML